At 11.9% CAGR, Asia Pacific Custom Antibody Services Market is Projected to be Worth US$ 167.86 Million by 2031, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific custom antibody services market was valued at US$ 68.24 million in 2023 and is expected to reach US$ 167.86 million by 2031, registering a CAGR of 11.9% from 2023 to 2031. Rise in government research and development activities in emerging and developed economies and rising approvals of biosimilars are among the critical factors attributed to the Asia Pacific custom antibody services market expansion.

Governments of emerging countries are launching several research and development initiatives focusing on genomics and proteomic methods. Asia has emerged as a center for innovation in genomics, particularly through initiatives. For instance, The Proteomics Society, an organization in India, aims to promote the field of proteomics and the professional interests of the Proteomics Community in the country. The organization also helps in facilitating research collaborations and workshops, driving the demand for custom antibody products. Countries such as China, Japan, and India are making significant investments in genomic research. For instance, the China Precision Medicine Initiative and India's Genome India Project aim to map genetic variations and improve personalized medicine. These endeavors receive support from both government funding and private sector investments, demonstrating a strong commitment to advancing genomics in the region. Therefore, the rise in research and development initiatives by governments of various developing economies is expected to create lucrative opportunities for the growth of the custom antibody services market during the forecast period.

On the contrary, high costs and complexities associated with antibody production using transgenic animals hamper the growth of Asia Pacific custom antibody services market.

Based on product type, the Asia Pacific custom antibody services market is segmented into monoclonal, polyclonal hybridoma, recombinant antibody, and others. The monoclonal segment held 49.7% share of the Asia Pacific custom antibody services market in 2023, amassing US$ 33.90 million. It is projected to garner US$ 80.82 million by 2031 to expand at 11.5% CAGR during 2023-2031.

Based on service type, the Asia Pacific custom antibody services market is segmented into antibody discovery and development, antibody production services, and others. The antibody discovery and development segment held 71.0% share of the Asia Pacific custom antibody services market in 2023, amassing US$ 48.44 million. It is projected to garner US$ 120.22 million by 2031 to expand at 12.0% CAGR during 2023-2031.

Based on application, the Asia Pacific custom antibody services market is segmented into immunohistochemistry, western blot & IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. The ELISA segment held 40.1% share of the Asia Pacific custom antibody services market in 2023, amassing US$ 27.39 million. It is projected to garner US$ 65.17 million by 2031 to expand at 11.4% CAGR during 2023-2031.

Based on disease indication, the Asia Pacific custom antibody services market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others. The oncology segment held 49.7% share of the Asia Pacific custom antibody services market in 2023, amassing US$ 33.91 million. It is projected to garner US$ 86.38 million by 2031 to expand at 12.4% CAGR during 2023-2031.

Based on source, the Asia Pacific custom antibody services market is segmented into chicken, rabbits, rats, guinea pigs, mouse or humanized mice, and others. The mouse or humanized mice segment held 39.6% share of the Asia Pacific custom antibody services market in 2023, amassing US$ 27.04 million. It is projected to garner US$ 64.49 million by 2031 to expand at 11.5% CAGR during 2023-2031. The mouse or humanized mice segment is further sub segmented into monoclonal antibody platform, BsAB discovery platform, bispecific ADC platform, TCR-mimic antibody platform, Anti-GPCR antibody technology platform, and others.

Based on end user, the Asia Pacific custom antibody services market is segmented into life science industry, pharmaceutical & biotech companies, academic & research institutes, and contract research organizations. The life science industry segment held 36.4% share of the Asia Pacific custom antibody services market in 2023, amassing US$ 24.83 million. It is projected to garner US$ 60.40 million by 2031 to expand at 11.8% CAGR during 2023-2031.

Based on country, the Asia Pacific custom antibody services market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. China held 28.0% share of Asia Pacific custom antibody services market in 2023, amassing US$ 19.13 million. It is projected to garner US$ 44.77 million by 2031 to expand at 11.2% CAGR during 2023-2031.

Key players operating in the custom antibody services market are Thermo Fisher Scientific Inc; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody (A&G Pharmaceutical, Inc.; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc; Bioklone; and Scantibodies Laboratory, Inc., among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com